Founder Lessons on Raising $100M for a High-Stakes Startup

Selling your company is the dream. For Cosmo Feilding Mellen, an $80 million exit was just the beginning. Now he’s tackling a far harder problem: developing psychedelic medicines to treat neurological and psychiatric disorders. His new company, Beckley Psytech, has raised nearly $100 million to do it.

His journey is a playbook for any founder with ambitions beyond a simple SaaS app. It reveals how to leverage a prior success, raise serious capital for a high-stakes venture, and navigate a heavily regulated industry. If you’re thinking about your second act, or want to tackle a "hard tech" problem from day one, this is what you need to know.

The Second-Time Founder Superpower: De-Risking the Impossible

An $80 million exit doesn't just give you capital; it gives you credibility. For investors, a second-time founder who has already returned capital is massively de-risked. You’ve proven you can build a team, ship a product, and navigate a company to a successful outcome.

This changes the fundraising conversation entirely. Instead of "Can you build a company?" the question becomes "Is this new market big enough?" and "Is your insight correct?" You get the benefit of the doubt on execution.

Common Mistake: The Halo Effect

The biggest trap for a successful second-time founder is arrogance. Your last success doesn't guarantee your next one. You still need to do the work: validate the market, talk to customers (or in this case, scientists and clinicians), and build a world-class team. Your reputation might get you the first meeting, but it won’t get a term sheet if the underlying business is weak.

Tackling Regulated Markets: A Different Kind of Startup

Beckley Psytech is not a typical startup. It’s a clinical-stage biopharmaceutical company. This isn’t about agile development and moving fast and breaking things. It’s about methodical, rigorous, and expensive scientific research governed by bodies like the FDA.

For founders considering a similar path in biotech, climate tech, or deep tech, you must internalize these differences:

Timelines are measured in years, not months. A single clinical trial can take years and cost tens of millions of dollars. The entire journey from lab to market can be a 10-15 year odyssey. · Your "MVP" is a data package. You aren't shipping code; you're presenting rigorous scientific data to prove safety and efficacy. Your success depends on the outcomes of controlled trials. · The regulatory moat is the business. While SaaS companies try to build moats through network effects, your moat in a pharma business is the regulatory approval. It’s incredibly difficult and expensive for a competitor to follow you.

Finding the Right Investors

Your standard SaaS VC is useless here. They don’t have the expertise to diligence the science or the patience for the timelines. You need specialist investors. Beckley Psytech’s cap table is a blueprint for this, including firms like Leafy Tunnel, Palo Santo Fund, Delphi VC, and What If Ventures . These investors have PhDs on staff and understand the nuances of clinical development.

Investor Red Flag Checklist: Avoid VCs who ask for monthly recurring revenue (MRR) charts, don’t have any scientists on their team, or expect a product launch in 18 months. They don’t understand your business and will be a nightmare to manage.

The Anatomy of a $100M "Moonshot" Raise

Raising nearly $100 million for a pre-revenue company seems impossible. It’s not, but it requires a different kind of fundraising strategy. You aren’t selling a vision of future revenue; you are selling a detailed, milestone-driven plan to get through specific, expensive phases of clinical trials.

Your Use of Funds Is the Story

A $100M raise for a company like Beckley Psytech isn't for hiring salespeople. It's meticulously budgeted for specific scientific goals:

Phase I Trials (Safety): ~$10M - $20M to prove a drug is safe in a small group of healthy volunteers. · Phase II Trials (Efficacy): ~$20M - $70M to test the drug's effectiveness in patients with the target condition. This is often the biggest value inflection point. · Team & G&A: Hiring world-class scientists, clinicians, and regulatory experts.

Your fundraising deck isn't a set of growth projections; it's a detailed project plan that shows investors exactly what scientific questions their capital will answer.

The Nuance of Biotech Valuation

Valuation in this world isn't a multiple of revenue. It’s based on the probability-adjusted future value of a potential blockbuster drug. Investors are underwriting a binary outcome: either the drug works and the company is worth billions, or it fails and it’s worth zero. The valuation is a reflection of how far along you are on that path and the size of the potential market you’re addressing.

A large raise doesn't mean insane dilution. By raising a large amount at a significant valuation step-up after proving a key milestone, you can often manage dilution effectively. For example, raising $80M on a $400M pre-money valuation is 16.7% dilution—a tolerable cost to fund the next several years of development.

Advice Before You Start a High-Stakes Venture

The journey of building a company like this is a marathon. The source podcast mentions Cosmo’s "top advice before starting your own company." For a venture of this magnitude, that advice centers on radical self-assessment.

Ask Yourself These Four Questions

Is my passion durable enough for a 15-year journey? You will face years of setbacks, failed experiments, and regulatory hurdles. Surface-level interest won’t be enough to survive the "trough of sorrow." · Do I have a unique scientific or regulatory insight? Why are you the person to solve this? Do you have access to unique IP, a world-class scientific co-founder, or a novel approach that others have missed? · Can I attract and lead PhDs and MDs? This is about building a culture of scientific excellence, not a sales floor. You need to be credible and compelling to people who are at the top of their scientific fields. · Am I prepared for the fundraising reality? A capital-intensive business means you are always fundraising. You must be able to compellingly articulate a complex scientific story to a niche group of investors, over and over again.

How to Apply This This Week

Audit your ambition. Are you working on a problem big enough to sustain you for a decade? If not, what would a bigger, harder version of your company look like? · Map your "regulatory moat." Even if you're not in pharma, is there a regulatory, legal, or other non-obvious moat you could be building? Spend two hours this week analyzing the regulations in your industry for opportunities. · Identify your specialist investors. Find the top 5 investors who focus exclusively on your specific sector. Study their portfolio companies and the backgrounds of their partners. Are they a fit for you? · De-risk your own profile. You may not have an $80M exit, but what can you do to prove you are a top-tier operator? Write an expert blog, build a reputation on social media, or advise other startups to build your credibility.